Fernández-Tajes, Juan
Gaulton, Kyle J.
van de Bunt, Martijn
Torres, Jason
Thurner, Matthias
Mahajan, Anubha
Gloyn, Anna L.
Lage, Kasper
McCarthy, Mark I.
Funding for this research was provided by:
Wellcome Trust (095101, 090532, 200837, 203141, 098381)
Wellcome Trust (106130, 090367)
National Institutes of Health (U01DK105535, R01MH090941, R01DK098032, U01DK085545)
National Institutes of Health (R01MH101814)
Medical Research Council (G0601261, MR/L020149/1)
Horizon 2020 (667191)
Novo Nordisk Fonden (NNF15CC0018486)
Article History
Received: 6 October 2018
Accepted: 8 March 2019
First Online: 26 March 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: MIM serves on advisory panels for Pfizer, NovoNordisk, Zoe Global; has received honoraria from Pfizer, NovoNordisk, Sanofi-Aventis and Eli Lilly; has stock options in Zoe Global and has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi-Aventis, Servier, Takeda. We would like to clarify that Novo Nordisk Foundation in organisational terms is responsible for awarding grants and Novo Holdings A/S manages the Foundation’s commercial activities.The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.